Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Phase 3 Recruiting 380 enrolled ABX advanced biochemical compounds GmbH

NaSingle-groupOpen-labelDiagnostic

Summary

This study assess the Diagnostic Performance of \[18F\]PSMA-1007 PET/CT Imaging in Patients with Newly-Diagnosed High-Risk or Very-High-Risk Prostate Cancer

Timeline

Start: 2024-06-13
Primary completion: 2027-03
Completion: 2027-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	18F-PSMA-1007	Diagnostic / imaging agent	—	Intravenous

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

Summary

Timeline

Drugs

Indications